Preparation and evaluation of a chitosan salt–poloxamer 407 based matrix for buccal drug delivery
Introduction
The buccal route presents several advantages compared to traditional methods of systemic drug administration [1], [2]. The direct entry of the drug into the systemic circulation obviates the first pass hepatic metabolism; in addition, the drug can be easily administered and, if necessary, removed from the site of application which is easily accessible for self-medication. By contrast, some drawbacks must be taken into account when a dosage form is proposed for buccal administration. Among these is the need for the device to maintain its position for many hours against buccal motion and salivary flow, the latter also being responsible for dissolving a possible relevant part of the drug, thus reducing the mucosal absorption. Consequently, the dosage form must have good adhesive properties and show an efficient control of drug delivery. This can be accomplished by using excipients with adequate characteristics. Numerous bioadhesive polymers have been investigated for purposes of buccal administration, namely, sodium carboxymethylcellulose, hydroxypropylcellulose, Carbopol, and polycarbophil [3], [4]. Another interesting polymer, chitosan, mixed with sodium alginate, was studied as a vehicle in buccal tablets [5], while chitosan glutamate, interacted with polycarbophil and other anionic polymers, was proposed for bilaminated films and bilayered tablets. It has been shown that drug release is influenced by swelling and erosion of the matrix, whereas matrix adhesiveness can be modulated using different mixtures of polymers, both adhesive and not [6].
In this paper, we propose a matrix for buccal drug delivery, composed of a chitosan salt and poloxamer 407 (P407). Chitosan is the N-deacetylated product of chitin, a polysaccharide very abundant in nature. Chitosan is gaining increasing importance in the pharmaceutical field due to its favourable properties such as biocompatibility, nontoxicity, and biodegradability.
It has been shown that this polymer has good mucoadhesiveness and a significant enhancing effect on the permeation of drugs across the buccal mucosa [7], [8]. P407, also known as pluronic F127, is a polyoxyethylene–polyoxypropylene–polyoxyethylene type block copolymer consisting of 70% polyoxyethylene units. It has the ability to form a clear gel in aqueous media at a concentration of approximately 20% (w/w) or more and exhibits the unique property of reversible thermal gelation; this latter is achieved at a higher temperature (e.g., body temperature) and is reversible upon cooling (e.g., at refrigerator temperature) thereby yielding a low viscosity solution. In addition, P407 has low toxicity, high solubilizing capacity, and excellent drug-release characteristics, all of which have been exploited in the polymer's use as a drug delivery vehicle for a variety of therapeutic agents [9], [10], [11].
The combination of chitosan acetate with P407 has been adopted for a mucosal vaccine delivery system, in which the two components showed a synergistic effect on the immune response [12]. P407 was also used in association with Carbopol to obtain mucoadhesive gels [13]. Taking into account the fact that chitosan salts have different physical properties and can have different effects on mucosa permeability [14], [15], [16], the aim of this work was to study the behaviour of a matrix composed of a chitosan salt and P407, investigating the effect of the type of chitosan salt and of the proportions of the components on matrix swelling, release capacity, and adhesion. It was expected that P407 could play an important role, based on its capacity of gelling during matrix hydration and the possibility of interaction with chitosan through hydrogen bonding.
Propranolol hydrochloride, a water-soluble compound and a widely used β-blocker, was selected as a model drug, as it is among those drugs whose systemic bioavailability might be strongly improved by buccal delivery.
Section snippets
Materials
P407 (Lutrol F 127®), was a kind gift from BASF, Milan, Italy. Medium molecular weight chitosan [molecular weight about 400 000, viscosity 286 mPa s at C=1% (w/w) in 1% (w/w) acetic acid, deacetylation grade 81%], lactic acid aqueous solution [85% (w/w)], and propranolol hydrochloride were all purchased from Sigma Aldrich (Milwaukee, USA). All the other chemicals were of reagent grade. Water was purified using the Milli-Q Plus system (Millipore, USA).
Experimental design
In order to verify the influence of the type
Matrix preparation and set-up of experimental design
Matrices obtained as lyophilised residues were initially compressed at a lower force (0.7 kN) in order to obtain a relatively porous disc that could facilitate matrix rehydration. However, a preliminary investigation of their mucoadhesion capacity revealed that adhesion prevailed over cohesion, thus rendering impossible such type of measures. Inasmuch as matrices compressed at a much higher force gave a similar drug release and did not present that drawback, the subsequent work focused on discs
Conclusions
This study has demonstrated that the behaviour of a matrix composed of poloxamer 407 and a chitosan salt can differ based on the salt type and proportion of polymer. Drug release, matrix swelling, and erosion as well as mucoadhesion, depended significantly both on chitosan salt type and relative amount of poloxamer. Independently of chitosan salt type, mucoadhesion was significantly favoured when the P407 concentration in the matrix was about 30% (w/w). Chitosan lactate gave good sustained
Acknowledgements
This work was supported by a grant from MIUR (Ministero dell'Università e della Ricerca, Rome, Italy).
References (26)
- et al.
Buccal delivery systems using hydrogels
Adv. Drug Deliv. Rev.
(1993) - et al.
Absorption of drugs from the human oral cavity
Int. J. Pharm.
(1991) - et al.
Design and evaluation of sustained release and buccal adhesive propranolol hydrochloride tablets
J. Control. Release
(1996) - et al.
Drug release from oral mucosal tablets of chitosan and sodium alginate
Int. J. Pharm.
(1995) - et al.
The design and evaluation of chitosan: ethylcellulose mucoadhesive bilayered devices for buccal drug delivery
J. Control. Release
(1998) - et al.
Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407
J. Pharm. Sci.
(1996) - et al.
In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine
J. Pharm. Sci.
(1998) - et al.
Comparison of the effect of different chitosan-salts and N-trimethyl-chitosan chloride on the permeability of intestinal epithelial cells (Caco-2)
J. Control. Release
(1998) - et al.
Moist heat treatment on physicochemical change of chitosan salt films
Int. J. Pharm.
(2002) - et al.
Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers
Int. J. Pharm.
(1997)
Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy
Int. J. Pharm.
A simple equation for description of solute release: II. Fickian and anomalous release from swellable devices
J. Control. Release
Moist heat treatment on physicochemical change of chitosan salt films
Int. J. Pharm.
Cited by (66)
Applications Of Chitosan Based Bionanocomposites In Drug-Delivery And Anticancer Treatment-A Review
2023, European Polymer JournalTargeted delivery via albumin corona nanocomplex to renal tubules to alleviate acute kidney injury
2022, Journal of Controlled Releasep-Coumaric acid loaded into liquid crystalline systems as a novel strategy to the treatment of vulvovaginal candidiasis
2021, International Journal of PharmaceuticsCitation Excerpt :Poloxamer 407 is a tri-block copolymer that consists of a central hydrophobic block of polypropylene glycol, flanked by two hydrophilic blocks of polyethylene glycol. In aqueous dispersions, it presents reversible thermal gelation, for instance, a dispersion with 20–30% poloxamer is fluid between 4 and 5 °C, however, at body temperature, it forms highly viscous gels (Bentley et al., 1999; Cafaggi et al., 2005). Due to the unique physicochemical properties and microstructures of LCs, there has been a great interest in the development of such liquid crystalline formulations for controlled drug release (Chaudhary et al., 2016).
Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer
2020, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :Poloxamer P188 (P188) was added to increase P407 Tsol-gel and reduce gelling time [31]. Alginate and chitosan were included as natural, biocompatible and biodegradable polymers to impart adhesive, thickening and shear-thinning properties [32–34]. Alginate is a linear, water-soluble polysaccharide copolymer composed of longer homo-polymeric regions of mannuronate and guluronate, potentially separated by regions of alternating structure mannuronate-guluronate.
Applications of Polymers in Buccal Drug Delivery
2020, Applications of Polymers in Drug DeliveryMucoadhesive and mucus-penetrating polymers for drug delivery
2020, Nanotechnology for Oral Drug Delivery: From Concept to Applications